Contact Us | Press Office | About Us | Vaccines | International | Our Charity
Share this article
26th Nov 2021
Researchers running the University of Oxford-led Com-COV programme have started enrolling young people aged 12 to 16 years old to receive a second dose of a COVID-19 vaccine, including in Alder Hey.
Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR) and run across several NIHR-supported sites by the National Immunisation Schedule Evaluation Consortium, the Com-COV 3 trial is seeking to recruit 360 volunteers. The study has already opened at six sites in the UK, and is expanding to nine new recruiting areas, with recruitment happening locally at Alder Hey.
Professor Matthew Snape, Associate Professor in Paediatrics and Vaccinology at the Oxford Vaccine Group, and Chief Investigator on the trial, said: “Teenagers are currently experiencing the highest rate of infections of all age groups in the UK. This study will be critical to delivering vital information on the range of options for immunising teenagers against COVID-19 in the UK to help control this. Therefore, we are asking for 12 to 16 years olds to take this opportunity to receive a second dose of vaccine and help us understand how best to immunise teenagers to protect them and their families.”
All participants will be randomly allocated at the time of their second dose to receive either a full second dose of the Pfizer vaccine, a one-third dose of the Pfizer vaccine, a full dose of the Novavax vaccine or a half dose of the Moderna vaccine. These vaccines will be administered at least eight weeks after their first dose, and sites hope to complete this stage of the study by early December.
Professor Andrew Ustianowski, NIHR Clinical Lead for COVID-19 Vaccination Programme and Joint National Infection Specialty Lead, said: “By getting involved in this study, volunteers will be able to help researchers develop our understanding of how we can best protect teenagers against COVID-19.
“Thanks to the generosity of thousands of vaccine study participants over the past 18 months, we have been able to reduce the impact and spread of COVID-19 with approved vaccines. Once it has reached its target, Com-COV 3 will be a pivotal study that is expected to provide important data that will lead directly to UK guidance on protecting young people and their families.”
If you would like to participate in the trial, you can sign up at - https://comcovstudy.org.uk/participate-alderhey-comcov3 or email AdolescentVaccine@alderhey.nhs.uk
Alder Hey Children's Charity